Tarceva News and Research

RSS
Tarceva is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Tarceva is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib, erlotinib hydrochloride, and OSI-774.
Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

OSI Pharmaceuticals reports total revenues of  $111 million for the third quarter of 2009

OSI Pharmaceuticals reports total revenues of $111 million for the third quarter of 2009

Ethnicity plays a significant role in non-small cell lung cancer genetics: Study

Ethnicity plays a significant role in non-small cell lung cancer genetics: Study

Memorial Sloan-Kettering Cancer Center awards $50,000 to three young investigators

Memorial Sloan-Kettering Cancer Center awards $50,000 to three young investigators

Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies

Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies

Winners of Paul Marks Prize 2009

Winners of Paul Marks Prize 2009

Phase 2 clinical trial results of IMO-2055 announced

Phase 2 clinical trial results of IMO-2055 announced

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Notice of Allowance issued by PTO for OSI's EGFR drug

Notice of Allowance issued by PTO for OSI's EGFR drug

IntrinsiQ's first IntelliView 360 research study results released

IntrinsiQ's first IntelliView 360 research study results released

OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor

OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

Tarceva shown to extend survival in advanced non-small cell lung cancer when used after initial chemo

Tarceva shown to extend survival in advanced non-small cell lung cancer when used after initial chemo

Drug combo improves outcome for advanced non-small cell lung cancer

Drug combo improves outcome for advanced non-small cell lung cancer

Cancer drugs erlotinib and gefitinib might treat alcoholism

Cancer drugs erlotinib and gefitinib might treat alcoholism

Mylan confirms four first-to-file challenges

Mylan confirms four first-to-file challenges

Gefitinib just as effective as chemotherapy for lung cancer

Gefitinib just as effective as chemotherapy for lung cancer

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Microchip-based device determines the genetic signature of lung tumors

Microchip-based device determines the genetic signature of lung tumors

Targeted therapy can improve outcomes for lung tumors

Targeted therapy can improve outcomes for lung tumors